Cytokinetics, Inc. (NASDAQ:CYTK) announced that results from the expansion phase of COSMIC-HF (ChronicOral Study of Myosin Activation to Increase Contractility in Heart Failure), a Phase 2 trial evaluatingomecamtiv mecarbil in patients with chronic heart failure, will be presented in the Late Breaking Clinical Trial Session at the American Heart Association Scientific Sessions 2015 on November 8 in Orlando, FL.
Date: Sunday, November 8, 2015
Session Time: 3:45-5:00 p.m. ET (Hall D)
Presentation Time: 4:31-4:40 p.m. ET
Session: LBCT.01 Failure is Not an Option: New Drugs and Systems of Care
Presentation Title: Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Final Results from a Double-blind, Randomized, Placebo-controlled, Multicenter Study
The Company will host an investor meeting and Webcast the following day, Monday, November 9, 2015 from 7:00 AM – 8:00 AM ET in Salon 10 of the Rosen Center. (Original Source)
Shares of Cytokinetics closed yesterday at $10.36. CYTK has a 1-year high of $10.75 and a 1-year low of $3.98. The stock’s 50-day moving average is $7.45 and its 200-day moving average is $6.83.
On the ratings front, Cytokinetics has been the subject of a number of recent research reports. In a report issued on October 23, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on CYTK, with a price target of $18, which implies an upside of 73.7% from current levels. Separately, on September 15, FBR’s Vernon Bernardino reiterated a Buy rating on the stock and has a price target of $14.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Pantginis and Vernon Bernardino have a total average return of -4.2% and -18.8% respectively. Pantginis has a success rate of 37.2% and is ranked #3730 out of 3827 analysts, while Bernardino has a success rate of 25.9% and is ranked #3800.
Cytokinetics Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.